Royal Bank of Canada
MLTX icon

Royal Bank of Canada’s MoonLake Immunotherapeutics MLTX Stock Holding History

Royal Bank of Canada’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2K Sell
84
-19
-18% -$315 ﹤0.01% 6721
2025
Q4 		$2K Sell
103
-48,195
-100% -$569K ﹤0.01% 6912
2025
Q3 		$346K Buy
48,298
+26,441
+121% +$1.38M ﹤0.01% 4742
2025
Q2 		$1.03M Buy
21,857
+6,303
+41% +$257K ﹤0.01% 3872
2025
Q1 		$608K Sell
15,554
-341
-2% -$14.7K ﹤0.01% 3848
2024
Q4 		$861K Buy
15,895
+1,343
+9% +$68.6K ﹤0.01% 3677
2024
Q3 		$733K Sell
14,552
-3,284
-18% -$154K ﹤0.01% 3790
2024
Q2 		$784K Sell
17,836
-79,638
-82% -$3.37M ﹤0.01% 3647
2024
Q1 		$4.89M Buy
97,474
+70,686
+264% +$3.83M ﹤0.01% 2192
2023
Q4 		$1.62M Buy
26,788
+2,705
+11% +$139K ﹤0.01% 3242
2023
Q3 		$1.37M Buy
24,083
+3,887
+19% +$215K ﹤0.01% 3172
2023
Q2 		$1.03M Buy
20,196
+19,540
+2,979% +$526K ﹤0.01% 3354
2023
Q1 		$14K Buy
656
+580
+763% +$9.75K ﹤0.01% 6172
2022
Q4 		$1K Buy
+76
New +$676 ﹤0.01% 7051

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada's MLTX Position: Q1 2026 in Review

Royal Bank of Canada reduced its MoonLake Immunotherapeutics (MLTX) stake by 18% in Q1 2026, selling an estimated $315 and leaving 84 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #6721.

Royal Bank of Canada first reported a position in MLTX in Q4 2022 and has held it in 14 quarters since. The position peaked at $4.89M in Q1 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Royal Bank of Canada held 84 shares of MoonLake Immunotherapeutics worth $2K as of Q1 2026.
  • Royal Bank of Canada sold 19 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $315.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6721 holding.
  • Royal Bank of Canada first reported a position in MoonLake Immunotherapeutics in Q4 2022 and has held it in 14 quarters since.
  • Royal Bank of Canada's MoonLake Immunotherapeutics position peaked at $4.89M in Q1 2024.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.